In this sense, the somatostatin, cortistatin and somatostatin-receptors (SST/CORT/SSTRs) system represents a useful source of diagnostic/prognostic biomarkers and therapeutic targets to manage and treat various endocrine-related cancers (ERCs), owing to its pleiotropic functional role encompassing whole body homeostasis to cancer cell functioning in different tumor types, wherein this system commonly acts to inhibit multiple processes, such as hormone secretion and cell proliferation, migration and invasion [12,13,14,15,16,17]. Here, CORT is linked to neoplasm.